Delivery Order SPE2DR25D1017-SPE2DR26F8YYC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Gemtesa 75 mg tablets in quantities of 90 units, with a ceiling value of $16,082.59. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of October 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,914.29 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count packaging) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price contract valued at $43,743.38. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 17, 2025. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $7,385.86. This firm fixed-price delivery order, with an ultimate completion date of October 21, 2025, represents a non-competitive award under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The order will be fulfilled from AmerisourceBergen's Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on August 18, 2025, with a ceiling value of $10,325.86. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order represents a single transaction...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Gemtesa 75 mg tablets (90-count) valued at $1,988.78. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for completion by September 18, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $21,108.85. This firm fixed-price delivery order, with an ultimate completion date of October 23, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $7,448.66 delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Gemtesa 75 mg tablets (90 count). This is a firm fixed price, non-set-aside contract with a completion date of April 23, 2025, and performance to be executed in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger pharmaceutical supply agreement with the DLA. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) at a ceiling value of $2,378.33. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on August 29, 2025, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F8YYCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $3,103.31. This firm fixed-price delivery order, which is expected to be completed by November 4, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal procurement standards. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies a comprehensive range of medications and medical products to support military and veteran healthcare systems. The Gemtesa delivery represents one of many pharmaceutical orders executed under this strategic contract vehicle, which enables the company to provide essential medications across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 11/3/25 |